Crescendo Biologics appoints new CMO

Pavel Pisa is the former Head of Translational Medicine at Roche and Genentech and has led over 50 programmes through early and late clinical development.

He was Professor of Clinical Experimental Oncology at the Karolinska Institutet, Stockholm and has held positions at NIH, MD Anderson Cancer Center and Scripps Research Institute.

Pavel holds a medical degree and a doctorate in medicine in Natural Killer Cells in the Clinic from Charles University, Prague, as well as a PhD in Immunology from the Karolinska Institutet.

Peter Pack, Chief Executive of Crescendo Biologics, said:
“We are delighted to welcome Pavel, a world-class immuno-oncologist, as our Chief Medical Officer. Pavel is the ideal person to drive our lead programme, CD137-PSMA, and our follow-on pipeline of immune modulators through the clinic. He brings with him truly exceptional experience as a clinical developer of oncology biologics, having previously led so many programmes for Roche in the IO field.
This appointment confirms Crescendo’s transition into a leading developer of differentiated, T-cell enhancing therapies.”